



PRESS RELEASE

26 April 2024 14:59:00 CEST

AcouWash placed at two potential OEM partners

In line with the company's ambition to increase revenues from its benchtop innovation systems, AcouSort has recently initiated two AcouWash lease collaborations with potential OEM partners, one in Europe and one in the US. The benchtop systems are important tools to enable easy access to AcouSort's unique technology for researchers and potential OEM partners alike.

The first lease is an initial three-month rental to a European based company active within the cell therapy space. Compared to some of AcouSort's other partners, the company is relatively small but has a very interesting innovation agenda. This new partner will use the AcouWash system to evaluate and optimize acoustic sample preparation for multiple sample preparation steps within its manufacturing process. The collaboration also contains an application support package to ensure that the partner has the optimal conditions to perform a successful and efficient evaluation.

The second AcouWash lease is an initial one-month rental to a US based company to evaluate sample preparation and cell wash for cytometry-like applications. Also in this case, the lease is combined with an application support package.

"With the AcouWash the user can easily gain access to our technology for internal evaluations. The leasing of the AcouWash systems to these two new customers is a first step in what we hope will develop into long-term partnerships. Future discussions about possible next steps and integration will be initiated once our collaboration partners have a deeper understanding for how the technology works," says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

26 April 2024 14:59:00 CEST

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).